Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS (2002) terminology report: the ongoing debate. Neurourol Urodyn 2009;28:287
   PubMedGoogle Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14; discussion 14–15
   PubMed Web of Science ®Google Scholar
• Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Bladder Dysfunct Rep 2006;1:52-60
   Google Scholar
• Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005;6:410-8
   PubMedGoogle Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
   PubMed Web of Science ®Google Scholar
• Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004;64(6 Suppl 1):2-6
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005;25:511-9
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-9
   PubMed Web of Science ®Google Scholar
• Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother 2008;55:89-95
   Google Scholar
• Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77(5):1081-7
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Zuckerman IH, McNally D, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009;15(4 Suppl):S90-7
   PubMedGoogle Scholar
• Wyman JF, Klutke C, Burgio K, et al. Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol 2010;17:5283-90
   PubMed Web of Science ®Google Scholar
• Wang AC, Chen MC, Kuo WY, et al. Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. Int Urogynecol J 2009;20:819-25
   Google Scholar
• Toglia MR, Serels SR, Laramee C, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med 2009;121:151-8
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007;99:836-44
   PubMed Web of Science ®Google Scholar
• Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006;60:752-8
   PubMed Web of Science ®Google Scholar
• Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatr Pharmacother 2009;7:373-82
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Sears CL, Lewis C, Noel K, et al. Overactive bladder medication adherence when medication is free to patients. J Urol 2010;183:1077-81
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
   PubMed Web of Science ®Google Scholar
• Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008;102:1128-32
   PubMed Web of Science ®Google Scholar
• Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43
   PubMed Web of Science ®Google Scholar
• Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-9
   PubMedGoogle Scholar
• Zorn BH, Montgomery H, Pieper K, et al. Urinary incontinence and depression. J Urol 1999;162:82-4
   PubMed Web of Science ®Google Scholar
• Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002;8:343-52
   PubMedGoogle Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181:1764-72
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-5
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008;71:449-54
   PubMed Web of Science ®Google Scholar
• Sand PK, Dmochowski RR, Zinner NR, et al. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1431-8
   PubMedGoogle Scholar
• Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn 2010;29:551-4
   PubMed Web of Science ®Google Scholar
• Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007;178:978-84
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009;63:1715-23
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Steers WD, et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60:959-66
   PubMed Web of Science ®Google Scholar
• Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001
   PubMed Web of Science ®Google Scholar
• Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-702
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzman S, Errando-Smet C, Trocio J, et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol 2011;11:9
   PubMed Web of Science ®Google Scholar
• Speakman M, Khullar V, Mundy A, et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-9
   PubMed Web of Science ®Google Scholar
• Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004;22:1047-59
   PubMed Web of Science ®Google Scholar
• Varadharajan S, Jumadilova Z, Girase P, et al. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005;11(4 Suppl):S140-9
   PubMedGoogle Scholar
• Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am J Manag Care 2005;11(4 Suppl):S150-7
   Google Scholar